{"id":1863,"date":"2017-02-08T12:10:30","date_gmt":"2017-02-08T12:10:30","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=1863"},"modified":"2024-09-18T15:31:55","modified_gmt":"2024-09-18T10:01:55","slug":"the-snippet-clinical-trials-need-to-assess-drug-efficacy-before-first-in-human-trials","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-snippet-clinical-trials-need-to-assess-drug-efficacy-before-first-in-human-trials","title":{"rendered":"Clinical trials need to assess drug efficacy before trials"},"content":{"rendered":"<p>On 17 January 2016, a healthy man was declared brain-dead after receiving an experimental drug in a first-in-human trial in France. Four of five other subjects receiving the same dose have serious, ongoing neurological complications. Investigations into the trial described many troubling safety practices, such as steep increases in dose levels delivered to sequential subjects without sufficient delays to check for safety. In the wake of the tragedies, the French medicines safety agency (ANSM) ordered an examination of the information that the drug developer, Bial, based in Trofa, Portugal, had supplied to ethics committees and potential researchers before the trial. The report notes that the 63-page Investigator Brochure describing the trial included fewer than two pages of evidence that the drug had the desired pharmacological activity. It identified only two studies presented as evidence for efficacy, both problematic. A lack of emphasis on evidence for the efficacy of drug candidates is all too common in decisions about whether an experimental medicine can be tested in humans. There is a need to call for infrastructure, resources and better methods to rigorously evaluate the clinical promise of new interventions before testing them on humans for the first time, to ensure safety from bogus medicines.<\/p>\n<h6>To know more, click <a href=\"http:\/\/www.nature.com\/news\/consider-drug-efficacy-before-first-in-human-trials-1.21384?WT.mc_id=SPG_NA_1702_FHCOMMENTDRUGEFFICACY_PORTFOLIO\">Clinical trials and drug efficacy<\/a>.<\/h6>\n<h6><\/h6>\n","protected":false},"excerpt":{"rendered":"<p>On 17 January 2016, a healthy man was declared brain-dead after receiving an experimental drug in a first-in-human trial in France. Four of five other subjects receiving the same dose have serious, ongoing neurological complications. Investigations into the trial described many troubling safety practices, such as steep increases in dose levels delivered to sequential subjects [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1520,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[168,773,775,774,739],"industry":[17225],"therapeutic_areas":[],"class_list":["post-1863","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-clinical-trial","tag-drug-regulation","tag-drug-safety-and-efficacy","tag-nature-journal","tag-snippet","industry-pharmaceutical"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Clinical trials for drug &amp; biologics | Delveinsight<\/title>\n<meta name=\"description\" content=\"On 17 January 2016, a healthy man was declared brain-dead after receiving an experimental drug in a first-in-human trial in France\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-snippet-clinical-trials-need-to-assess-drug-efficacy-before-first-in-human-trials\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Clinical trials for drug &amp; biologics | Delveinsight\" \/>\n<meta property=\"og:description\" content=\"On 17 January 2016, a healthy man was declared brain-dead after receiving an experimental drug in a first-in-human trial in France\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-snippet-clinical-trials-need-to-assess-drug-efficacy-before-first-in-human-trials\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-02-08T12:10:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-18T10:01:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/11\/12053920\/shutterstock_228917461_650.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"650\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Clinical trials for drug & biologics | Delveinsight","description":"On 17 January 2016, a healthy man was declared brain-dead after receiving an experimental drug in a first-in-human trial in France","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-snippet-clinical-trials-need-to-assess-drug-efficacy-before-first-in-human-trials","og_locale":"en_US","og_type":"article","og_title":"Clinical trials for drug & biologics | Delveinsight","og_description":"On 17 January 2016, a healthy man was declared brain-dead after receiving an experimental drug in a first-in-human trial in France","og_url":"https:\/\/www.delveinsight.com\/blog\/the-snippet-clinical-trials-need-to-assess-drug-efficacy-before-first-in-human-trials","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-02-08T12:10:30+00:00","article_modified_time":"2024-09-18T10:01:55+00:00","og_image":[{"width":650,"height":400,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/11\/12053920\/shutterstock_228917461_650.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-snippet-clinical-trials-need-to-assess-drug-efficacy-before-first-in-human-trials","url":"https:\/\/www.delveinsight.com\/blog\/the-snippet-clinical-trials-need-to-assess-drug-efficacy-before-first-in-human-trials","name":"Clinical trials for drug & biologics | Delveinsight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-snippet-clinical-trials-need-to-assess-drug-efficacy-before-first-in-human-trials#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-snippet-clinical-trials-need-to-assess-drug-efficacy-before-first-in-human-trials#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/11\/12053920\/shutterstock_228917461_650.jpg","datePublished":"2017-02-08T12:10:30+00:00","dateModified":"2024-09-18T10:01:55+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"On 17 January 2016, a healthy man was declared brain-dead after receiving an experimental drug in a first-in-human trial in France","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-snippet-clinical-trials-need-to-assess-drug-efficacy-before-first-in-human-trials"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-snippet-clinical-trials-need-to-assess-drug-efficacy-before-first-in-human-trials#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/11\/12053920\/shutterstock_228917461_650.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/11\/12053920\/shutterstock_228917461_650.jpg","width":650,"height":400},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/11\/12053920\/shutterstock_228917461_650-300x185.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">clinical trial<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Drug Regulation<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Drug Safety and Efficacy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Nature Journal<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippet<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">clinical trial<\/span>","<span class=\"advgb-post-tax-term\">Drug Regulation<\/span>","<span class=\"advgb-post-tax-term\">Drug Safety and Efficacy<\/span>","<span class=\"advgb-post-tax-term\">Nature Journal<\/span>","<span class=\"advgb-post-tax-term\">Snippet<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Feb 8, 2017","modified":"Updated on Sep 18, 2024"},"absolute_dates_time":{"created":"Posted on Feb 8, 2017 12:10 pm","modified":"Updated on Sep 18, 2024 3:31 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1863","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=1863"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1863\/revisions"}],"predecessor-version":[{"id":29645,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1863\/revisions\/29645"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1520"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=1863"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=1863"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=1863"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=1863"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=1863"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}